DeepMed Research

Chinese Academy of Medical Sciences Peking Union Medical College Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Registry Study of Extracorporeal Cardiopulmonary Resuscitation (eCPR) in China

Conditions: Cardiopulmonary Arrest
Extracorporeal Membrane Oxygenation Complication

First Posted Date: 2021-07-09

Last Posted Date: 2021-07-09

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 300

Registration Number: NCT04956497

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

Anlotinib or Penpulimab in Combination With RAI for DTC

Phase 2

Conditions: Thyroid Cancer

Interventions: Drug: Anlotinib hydrochloride
Drug: Sodium Iodide I 131
Drug: Penpulimab

First Posted Date: 2021-07-07

Last Posted Date: 2022-01-28

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 42

Registration Number: NCT04952493

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients

Phase 3

Conditions: Analgesia
Postoperative Pain

Interventions: Drug: Remimazolam Besylate
Drug: Propofol

First Posted Date: 2021-07-01

Last Posted Date: 2021-07-01

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 84

Registration Number: NCT04947345

A Mobile Application Based Dietary Self Management Intervention in Chinese Chronic Kidney Disease Patients

Not Applicable

Conditions: Chronic Renal Disease

Interventions: Behavioral: Mobile Application for Dietary Management

First Posted Date: 2021-06-28

Last Posted Date: 2021-06-28

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 9863

Registration Number: NCT04940819

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Diet-glucose-gut Microbiome Net in Women With GDM

Not Applicable

Conditions: GDM
Blood Glucose
Pregnancy Outcome
Microbiota

Interventions: Other: Diet intervention

First Posted Date: 2021-06-18

Last Posted Date: 2021-06-18

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 70

Registration Number: NCT04930276

Locations: 🇨🇳
Department of ob gyn , Peking Union Medical College Hospital, Beijing, Beijing, China

Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)

Phase 2

Conditions: COVID-19
SARS-CoV-2

Interventions: Drug: JS016

First Posted Date: 2021-06-18

Last Posted Date: 2021-10-21

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 200

Registration Number: NCT04931238

Locations: 🇨🇳
Shi Jiazhuang People's Hospital, Shijia Zhuang, He Bei, China
🇨🇳
The First Affliated Hospital of Harbin Medical University, Harbin, Hei Longjiang, China
🇨🇳
Suihua first hospital, Suihua, Hei Longjiang, China

and more 1 locations

Exploring Biomarkers in Age Stratified PUMCH Dementia Cohort

Recruiting

Conditions: Dementia With Lewy Bodies
Dementia Frontal
Dementia, Mixed
Dementia
Dementia Alzheimers
Dementia, Vascular

First Posted Date: 2021-06-14

Last Posted Date: 2022-09-13

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 2000

Registration Number: NCT04924361

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Lenalidomide and Dexamethasone for Rosai-Dorfman Disease

Phase 2

Recruiting

Conditions: Rosai-Dorfman Disease

Interventions: Drug: lenalidomide and dexamethasone

First Posted Date: 2021-06-14

Last Posted Date: 2021-06-16

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 16

Registration Number: NCT04924647

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China

A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients

Phase 1

Completed

Conditions: Sjogren's Syndrome

Interventions: Drug: Baricitinib 2 MG

First Posted Date: 2021-06-08

Last Posted Date: 2021-06-30

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 11

Registration Number: NCT04916756

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Intravascular Large B-Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vindesine
Drug: Prednisone

First Posted Date: 2021-05-24

Last Posted Date: 2021-05-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT04899570

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy